当前位置： SCI文献检索 > CLINICAL PHARMACOKINETICS期刊下所有文献 > A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.

Abstract：

:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), vedolizumab is administered as a 300 mg intravenous infusion. Vedolizumab undergoes a rapid, saturable, non-linear, target-mediated elimination process at low concentrations and a slower, linear, non-specific elimination process at higher concentrations. At therapeutic concentrations, vedolizumab primarily undergoes linear elimination. From population pharmacokinetic modeling, the vedolizumab terminal elimination half-life (t ½ β) was estimated to be 25.5 days; linear clearance (CLL) was similar for patients with UC (0.159 L/day) and CD (0.155 L/day). Extreme low albumin concentrations and extreme high body weight values were potentially clinically important predictors of vedolizumab CLL. Other factors, including concomitant therapy use (methotrexate, azathioprine, mercaptopurine, or aminosalicylates) or prior tumor necrosis factor-α (TNF-α) antagonist use, had no clinically relevant effects on CLL. A positive exposure-efficacy relationship for clinical remission and clinical response was apparent for vedolizumab induction therapy in patients with UC or CD. On average, patients with higher albumin, lower fecal calprotectin (UC only), lower C-reactive protein (CD only), and no prior TNF-α antagonist use had a higher probability of remission. Off drug, 10% of patients with UC or CD were positive for anti-drug antibodies. This article provides a comprehensive review of the clinical pharmacokinetics, pharmacodynamics, exposure-efficacy relationships, and immunogenicity of vedolizumab.

journal_name

Clin Pharmacokinet

journal_title

Clinical pharmacokinetics

authors

Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

doi

10.1007/s40262-017-0546-0

subject

Has Abstract

pub_date

2017-11-01 00:00:00

pages

1287-1301

issue

11

eissn

0312-5963

issn

1179-1926

pii

10.1007/s40262-017-0546-0

journal_volume

56

pub_type

杂志文章,评审

相关文献

CLINICAL PHARMACOKINETICS文献大全
  • Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.

    abstract：:The various components required for individualising clinical drug dosage regimens are reviewed, including a study of 3 types of fitting procedures, 2 types of gentamicin pharmacokinetic model and the utility of D-optimal times for obtaining serum gentamicin concentrations. The combination of the current Bayesian fitti...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199121060-00006

    authors： Jelliffe RW,Iglesias T,Hurst AK,Foo KA,Rodriguez J

    更新日期：1991-12-01 00:00:00

  • Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

    abstract：BACKGROUND:International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better understanding of the influence of ethnicity on drug response to minimize duplication of clinical studies, thereby expediting drug approval. OBJ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-013-0089-y

    authors： Barter ZE,Tucker GT,Rowland-Yeo K

    更新日期：2013-12-01 00:00:00

  • Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.

    abstract：BACKGROUND AND OBJECTIVE:The use of an opportunistic (also called scavenged) sampling strategy in a prospective pharmacokinetic study combined with population pharmacokinetic modelling has been proposed as an alternative strategy to conventional methods for accomplishing pharmacokinetic studies in neonates. However, th...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-015-0291-1

    authors： Leroux S,Turner MA,Guellec CB,Hill H,van den Anker JN,Kearns GL,Jacqz-Aigrain E,Zhao W,TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums.

    更新日期：2015-12-01 00:00:00

  • Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?

    abstract：:In the original publication, Page 3, Sect. 4.3, the first sentence was incorrectly published. ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,已发布勘误

    doi：10.1007/s40262-018-0633-x

    authors： Martin JH,Schneider J,Lucas CJ,Galettis P

    更新日期：2018-05-01 00:00:00

  • Salivary antipyrine half-life during injectable progestagen contraception.

    abstract：:Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198611020-00007

    authors： Joshi JV,Gupta KC,Hazari KT,Gokral J,Pohujani S,Satoskar R

    更新日期：1986-03-01 00:00:00

  • Plasma level monitoring of antipsychotic drugs. Clinical utility.

    abstract：:The steady-state plasma concentrations of antipsychotic drugs show large interpatient variations but remain relatively stable from day to day in each individual patient. Monitoring of antipsychotic drug concentrations in plasma might be of value provided the patients are treated with only 1 antipsychotic drug. Some st...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198611010-00003

    authors： Dahl SG

    更新日期：1986-01-01 00:00:00

  • Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime.

    abstract：BACKGROUND AND OBJECTIVE:Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-020-00873-3

    authors： Liu J,Neely M,Lipman J,Sime F,Roberts JA,Kiel PJ,Avedissian SN,Rhodes NJ,Scheetz MH

    更新日期：2020-08-01 00:00:00

  • Clinical Pharmacokinetics of Vemurafenib.

    abstract：:Vemurafenib is an orally administered small-molecule inhibitor of the oncogenic BRAF kinase that is indicated for the treatment of patients with unresectable or metastatic melanoma harbouring BRAF V600 mutations. Vemurafenib is absorbed rapidly after a single oral dose of 960 mg, reaching maximum drug concentration ap...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-017-0523-7

    authors： Zhang W,Heinzmann D,Grippo JF

    更新日期：2017-09-01 00:00:00

  • Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

    abstract：:The pharmacokinetics and cardiovascular effects of the calcium entry blocker nisoldipine (10 mg twice daily) were studied in 6 patients with renal failure (creatinine clearance 23 +/- 9 ml/min) and 6 healthy control subjects after a single dose and 1 week of oral administration. No significant differences in eliminati...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-198916010-00004

    authors： van Harten J,Burggraaf J,van Brummelen P,Breimer DD

    更新日期：1989-01-01 00:00:00

  • Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

    abstract：BACKGROUND AND AIMS:In this study, we evaluate the performance of allometric concepts to predict the implications of age and size on the pharmacokinetics of lamotrigine, and assess the dose rationale across different age groups from 0.2 to 91 years. METHODS:An allometrically scaled pharmacokinetic model was developed ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0614-5

    authors： van Dijkman SC,de Jager NCB,Rauwé WM,Danhof M,Della Pasqua O

    更新日期：2018-08-01 00:00:00

  • Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

    abstract：BACKGROUND AND OBJECTIVES:Caspofungin is an echinocandin antifungal agent used as first-line therapy for the treatment of invasive candidiasis. The maintenance dose is adapted to body weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the pharmacokinetics of caspofungin and assess pharmacokineti...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-015-0347-2

    authors： Martial LC,Brüggemann RJ,Schouten JA,van Leeuwen HJ,van Zanten AR,de Lange DW,Muilwijk EW,Verweij PE,Burger DM,Aarnoutse RE,Pickkers P,Dorlo TP

    更新日期：2016-06-01 00:00:00

  • Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin.

    abstract：:A method is presented for the simultaneous estimation of functional hepatic blood flow and intrinsic clearance. The method uses pharmacokinetic data of a therapeutically employed drug and one of its primary metabolites following intravenous and oral administration of the parent compound. When the disposition of the dr...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199223010-00006

    authors： Weber W,Looby M,Brockmöller J

    更新日期：1992-07-01 00:00:00

  • Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

    abstract：:This review describes the pharmacokinetics of the major drugs used for the treatment of inflammatory bowel disease. This information can be helpful for the selection of a particular agent and offers guidance for effective and well tolerated regimens. The corticosteroids have a short elimination half-life (t1/2beta) of...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200140100-00003

    authors： Schwab M,Klotz U

    更新日期：2001-01-01 00:00:00

  • Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients.

    abstract：BACKGROUND AND OBJECTIVE:Taurolidine is known to have antimicrobial activity. Furthermore, at lower concentrations, it has been found to exert a selective antineoplastic effect in vitro and in vivo. The aim of this study was to investigate the pharmacokinetics of taurolidine in vivo following repeated intravenous infus...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-200746060-00005

    authors： Stendel R,Scheurer L,Schlatterer K,Stalder U,Pfirrmann RW,Fiss I,Möhler H,Bigler L

    更新日期：2007-01-01 00:00:00

  • Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.

    abstract：:Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment of multiple sclerosis (MS) and is also used in chronic lymphocytic leukemia (CLL). Alemtuzumab is used off-label in kidney transplantation as ind...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-017-0573-x

    authors： van der Zwan M,Baan CC,van Gelder T,Hesselink DA

    更新日期：2018-02-01 00:00:00

  • A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.

    abstract：OBJECTIVE:The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. METHODS:Patients were enrolled in three independent parallel cohort...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s40262-016-0496-y

    authors： Li C,Agarwal P,Gibiansky E,Jin JY,Dent S,Gonçalves A,Nijem I,Strasak A,Harle-Yge ML,Chernyukhin N,LoRusso P,Girish S

    更新日期：2017-09-01 00:00:00

  • Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus.

    abstract：BACKGROUND:Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with active SE or a history of SE....

    journal_title：Clinical pharmacokinetics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s40262-016-0486-0

    authors： Gonzalez D,Chamberlain JM,Guptill JT,Cohen-Wolkowiez M,Harper B,Zhao J,Capparelli EV,Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.

    更新日期：2017-08-01 00:00:00

  • Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.

    abstract：:The disposition of simeprevir (SMV) in humans is characterised by cytochrome P450 3A4 metabolism and hepatic uptake by organic anion transporting polypeptide 1B1/3 (OATP1B1/3). This study was designed to investigate SMV plasma and liver exposure upon oral administration in subjects infected with hepatitis C virus (HCV...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.1007/s40262-016-0476-2

    authors： Snoeys J,Beumont M,Monshouwer M,Ouwerkerk-Mahadevan S

    更新日期：2017-07-01 00:00:00

  • Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

    abstract：:Drug-drug, drug-formulation and drug-meal interactions are of clinical concern for orally administered drugs that possess a narrow therapeutic index. This review presents the current status of information regarding interactions which may influence the gastrointestinal (GI) absorption of orally administered drugs. Abso...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199936030-00004

    authors： Fleisher D,Li C,Zhou Y,Pao LH,Karim A

    更新日期：1999-03-01 00:00:00

  • Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

    abstract：:Antipsychotics may cause serious adverse cardiovascular effects, including prolonged QT interval and sudden death. This review considers antipsychotic-induced cardiovascular events from three perspectives: high-risk drugs, high-risk individuals and high-risk drug interactions. Pharmacokinetic drug interactions involvi...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200443010-00003

    authors： Brown CS,Farmer RG,Soberman JE,Eichner SF

    更新日期：2004-01-01 00:00:00

  • Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.

    abstract：BACKGROUND AND OBJECTIVE:Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels ± other lipid-lowering therapies. We aimed to develop and qualify a population pharmacokinetics (PopPK) model for alirocumab in...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,meta分析

    doi：10.1007/s40262-016-0505-1

    authors： Djebli N,Martinez JM,Lohan L,Khier S,Brunet A,Hurbin F,Fabre D

    更新日期：2017-10-01 00:00:00

  • An updated comparison of drug dosing methods. Part IV: Vancomycin.

    abstract：:The resurgence of the use of and interest in vancomycin, in conjunction with the high degree of interpatient variability in its pharmacokinetic profile, has prompted the development of many and varied dosing methods. Several dosing nomograms have been proposed and evaluated, methods which are useful for initial dosing...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199120060-00003

    authors： Pryka RD,Rodvold KA,Erdman SM

    更新日期：1991-06-01 00:00:00

  • Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery?

    abstract：:The alignment of drug metabolism and pharmacokinetic departments with drug discovery has not produced a radical improvement in the pharmacokinetic properties of new chemical entities. The reason for this is complex, reflecting in part the difficulty of combining potency, selectivity, water solubility, metabolic stabil...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200241130-00001

    authors： Smith D,Schmid E,Jones B

    更新日期：2002-01-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of pegfilgrastim.

    abstract：:Pegfilgrastim is a sustained-duration form of filgrastim, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), to which a 20  kDa polyethylene glycol molecule is covalently bound to the N-terminal methionine residue. Similar to filgrastim, pegfilgrastim increases the proliferation and d...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/11586040-000000000-00000

    authors： Yang BB,Kido A

    更新日期：2011-05-01 00:00:00

  • Clinical pharmacokinetics of mifepristone.

    abstract：:Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone. The pharmacokinetics of mifepristone are characterised by rapid absorption, a ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章

    doi：10.2165/00003088-199733010-00002

    authors： Heikinheimo O

    更新日期：1997-07-01 00:00:00

  • Cost considerations in therapeutic drug monitoring of aminoglycosides.

    abstract：:Aminoglycoside antibiotics are very important in the treatment of Gram-negative infections and as synergistic agents for the treatment of staphylococcal and streptococcal (group B streptococci and enterococci) infections. However, these agents have a narrow therapeutic index. Thus, a number of new antibiotics have bee...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-199426010-00006

    authors： Bertino JS Jr,Rodvold KA,Destache CJ

    更新日期：1994-01-01 00:00:00

  • Pharmacokinetics of haloperidol.

    abstract：:Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-198917060-00004

    authors： Froemming JS,Lam YW,Jann MW,Davis CM

    更新日期：1989-12-01 00:00:00

  • Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

    abstract：:With the aging population and its rapidly increasing prevalence, dementia has become an important public health concern in developed and developing countries. To date, the pharmacological treatment is symptomatic and based on the observed neurotransmitter disturbances. The four most commonly used drugs are donepezil, ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.1007/s40262-013-0038-9

    authors： Noetzli M,Eap CB

    更新日期：2013-04-01 00:00:00

  • The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting.

    abstract：:Inadequate pain control in the postoperative period not only contributes to patient discomfort, but also causes physiological changes that may result in increased risk of myocardial ischaemia, deep vein thrombosis and pulmonary embolism. These events complicate postoperative recovery and may lead to longer hospital st...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200544001-00002

    authors： Sinatra R

    更新日期：2005-01-01 00:00:00

  • New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.

    abstract：:Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles ...

    journal_title：Clinical pharmacokinetics

    pub_type： 杂志文章,评审

    doi：10.2165/00003088-200847090-00003

    authors： Roach P

    更新日期：2008-01-01 00:00:00